The primary objective of the Scheme is to provide long-term capital appreciation by investing predominantly in equity and equity related instruments of Pharma and Healthcare companies. The Scheme does not guarantee/indicate any returns. However, there can be no assurance that the investment objective of the Scheme will be realized.
Expert-managed portfolios tailored to your financial goals and risk appetite.
| Sector Funds | 1M | 3M | 6M | 9M | 1Y | 2Y | 3Y | 4Y | 5Y | 10Y | ALL |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Fund returns | -6.9% | -4.25% | 7.29% | 8.49% | 2.6% | N/A | N/A | N/A | N/A | N/A | 0.38% |
| Category returns | -7.54% | -3.42% | 10.54% | 13.4% | 8.01% | 3.9% | 18.22% | 18.48% | 12.78% | 13.01% | N/A |
| Absolute returns | -6.9% | -4.25% | 7.29% | 8.49% | 2.6% | N/A | N/A | N/A | N/A | N/A | 0.5% |
| Rank within category | 4/19 | 13/18 | 15/18 | 15/18 | 14/17 | N/A | N/A | N/A | N/A | N/A | N/A |
| Sector Funds | 2025 | 2026 |
|---|---|---|
| Yearly returns | N/A | 6.24% |
| Q1 returns | N/A | -3.77% |
| Q2 returns | N/A | 12.7% |
| Q3 returns | -5.49% | 2.09% |
| Q4 returns | 0.1% | -4.05% |
NIL upto 10% of units and 1% for remaining units on or before 1Y, Nil after 1Y
| Alpha | 0.26832 |
| Beta | 0.4025 |
| Sharpe Ratio | -0.0453373 |
| Sortino Ratio | -0.0983481 |
| R-Squared | 0.1791 |
| Tracking Error | 3.6563 |
| Downside Risk | 10.5767 |
| Std. Deviation (Annualised) | 11.4815 |
| Sector Funds | 1M | 3M | 6M | 9M | 1Y | 3Y | 5Y | 10Y | ALL | Fund Size (Cr) | Exp. Ratio | Sharpe | Risk |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| HDFC Pharma and Healthcare Fund - Regular Plan - Growth | -8.18% | -2.85% | 13.49% | 19.65% | 16.65% | 26.3% | N/A | N/A | 26.16% | 3,501.37 | 2.11 | 0.45 | Very High |
| SBI Healthcare Opportunities Fund - Regular Plan - IDCW | -7.91% | -3.95% | 12% | 16.9% | 9.98% | 20.31% | 16% | 12.88% | 16.36% | 5,870.00 | 1.99 | 0.33 | Very High |
| UTI Healthcare Fund - Regular Plan - IDCW | -8.04% | -4.49% | 10.8% | 14.7% | 7.94% | 19.65% | 13.41% | 12.86% | 14.71% | 1,429.84 | 2.22 | 0.32 | Very High |
| Mirae Asset Healthcare Fund - Regular Plan - Growth | -6.65% | -2.37% | 10.95% | 15.8% | 10.86% | 19.1% | 13.11% | N/A | 19.31% | 3,494.44 | 2.04 | 0.30 | Very High |
| ICICI Prudential Healthcare Fund - Growth | -5.27% | -5.77% | 5.31% | 6.11% | 1.04% | 18.9% | 14.21% | N/A | 18.53% | 6,861.20 | 2.08 | 0.30 | Very High |
| LIC MF Healthcare Fund - Regular Plan - Growth | -8.31% | -3.16% | 10.44% | 10.22% | 4.45% | 18.2% | 9.97% | N/A | 16.14% | 99.36 | 2.67 | 0.28 | Very High |
| DSP Healthcare Fund - Regular Plan - Growth | -5.87% | -2.13% | 13.11% | 11.93% | 9.74% | 17.47% | 13.29% | N/A | 20.34% | 3,750.04 | 2.05 | 0.29 | Very High |
| Aditya Birla Sun Life Pharma & Healthcare Fund - Regular Plan - Growth | -7.92% | -5.04% | 8.82% | 11.15% | 7.84% | 16.89% | 11.54% | N/A | 18.16% | 1,077.52 | 2.29 | 0.27 | Very High |
| Quant Healthcare Fund - Regular Plan - Growth | -7.41% | -1.49% | 10.61% | 18.21% | 9.71% | 16.57% | N/A | N/A | 17.69% | 424.53 | 3.13 | 0.23 | Very High |
| Baroda BNP Paribas Health and Wellness Fund - Regular Plan - Growth Current | -6.9% | -4.25% | 7.29% | 8.49% | 2.6% | N/A | N/A | N/A | 0.38% | 487.35 | 2.74 | -0.05 | Very High |
| Name | Sector | Instrument | Assets % |
|---|---|---|---|
| Sun Pharmaceutical Industries Ltd. | Pharmaceuticals & Biotechnology | Domestic Equities | 8.58% |
| Torrent Pharmaceuticals Ltd. | Pharmaceuticals & Biotechnology | Domestic Equities | 7.88% |
| Divi's Laboratories Ltd. | Pharmaceuticals & Biotechnology | Domestic Equities | 7.82% |
| Ipca Laboratories Ltd. | Pharmaceuticals & Biotechnology | Domestic Equities | 6.13% |
| Laurus Labs Ltd. | Pharmaceuticals & Biotechnology | Domestic Equities | 6.09% |
| Lupin Ltd. | Pharmaceuticals & Biotechnology | Domestic Equities | 5.79% |
| Apollo Hospitals Enterprise Ltd. | Healthcare Services | Domestic Equities | 5.28% |
| Fortis Healthcare Ltd. | Healthcare Services | Domestic Equities | 3.98% |
| Dr. Lal Pathlabs Ltd. | Healthcare Services | Domestic Equities | 3.47% |
| Mankind Pharma Ltd. | Pharmaceuticals & Biotechnology | Domestic Equities | 3.34% |
| Glenmark Pharmaceuticals Ltd. | Pharmaceuticals & Biotechnology | Domestic Equities | 3.11% |
| Aurobindo Pharma Ltd. | Pharmaceuticals & Biotechnology | Domestic Equities | 3.09% |
| Astrazeneca Pharma India Ltd. | Pharmaceuticals & Biotechnology | Domestic Equities | 2.79% |
| Clearing Corporation of India Ltd | Cash & Cash Equivalents and Net Assets | 2.78% | |
| Abbott India Ltd. | Pharmaceuticals & Biotechnology | Domestic Equities | 2.50% |
| Emcure Pharmaceuticals Ltd. | Pharmaceuticals & Biotechnology | Domestic Equities | 2.39% |
| Acutaas Chemicals Ltd. | Pharmaceuticals & Biotechnology | Domestic Equities | 2.36% |
| Zydus Lifesciences Ltd. | Pharmaceuticals & Biotechnology | Domestic Equities | 2.24% |
| Max Financial Services Ltd. | Insurance | Domestic Equities | 2.21% |
| Aster DM Quality Care Ltd. | Healthcare Services | Domestic Equities | 2.15% |
| Concord Biotech Ltd. | Pharmaceuticals & Biotechnology | Domestic Equities | 2.11% |
| Ajanta Pharma Ltd. | Pharmaceuticals & Biotechnology | Domestic Equities | 1.56% |
| Symbiotec Pharmalab Ltd. | Pharmaceuticals & Biotechnology | Domestic Equities | 1.47% |
| Nephrocare Health Services Ltd. | Healthcare Services | Domestic Equities | 1.42% |
| Metropolis Healthcare Ltd. | Healthcare Services | Domestic Equities | 1.33% |
| Dr. Reddy's Laboratories Ltd. | Pharmaceuticals & Biotechnology | Domestic Equities | 1.26% |
| Manipal Health Enterprises Ltd. | Healthcare Services | Domestic Equities | 1.23% |
| Gland Pharma Ltd. | Pharmaceuticals & Biotechnology | Domestic Equities | 1.19% |
| Cipla Ltd. | Pharmaceuticals & Biotechnology | Domestic Equities | 1.10% |
| Narayana Hrudayalaya Ltd. | Healthcare Services | Domestic Equities | 0.97% |
| Inventurus Knowledge Solutions Ltd. | IT - Services | Domestic Equities | 0.90% |
| Glaxosmithkline Pharmaceuticals Ltd. | Pharmaceuticals & Biotechnology | Domestic Equities | 0.68% |
| Life Insurance Corporation of India | Insurance | Domestic Equities | 0.47% |
| Procter & Gamble Health Ltd. | Pharmaceuticals & Biotechnology | Domestic Equities | 0.17% |
| Net Receivables / (Payables) | Cash & Cash Equivalents and Net Assets | 0.14% | |
| Total | 100.00% | ||
Mr.Sanjay Chawla has overall experience of 22 years with over 15 years experience in Equity Research. Prior to this, worked with SBI Capital Markets.
Get personalized portfolio management services designed to grow and protect your wealth.
ChatGPT
Claude
Perplexity
